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Coexpression analysis of large cancer datasets
provides insight into the cellular phenotypes of
the tumour microenvironment
Tamasin N Doig1,3, David A Hume3, Thanasis Theocharidis3, John R Goodlad2, Christopher D Gregory1
and Tom C Freeman3*
Abstract
Background: Biopsies taken from individual tumours exhibit extensive differences in their cellular composition due
to the inherent heterogeneity of cancers and vagaries of sample collection. As a result genes expressed in specific
cell types, or associated with certain biological processes are detected at widely variable levels across samples in
transcriptomic analyses. This heterogeneity also means that the level of expression of genes expressed specifically
in a given cell type or process, will vary in line with the number of those cells within samples or activity of the
pathway, and will therefore be correlated in their expression.
Results: Using a novel 3D network-based approach we have analysed six large human cancer microarray datasets
derived from more than 1,000 individuals. Based upon this analysis, and without needing to isolate the individual
cells, we have defined a broad spectrum of cell-type and pathway-specific gene signatures present in cancer
expression data which were also found to be largely conserved in a number of independent datasets.
Conclusions: The conserved signature of the tumour-associated macrophage is shown to be largely-independent
of tumour cell type. All stromal cell signatures have some degree of correlation with each other, since they must all
be inversely correlated with the tumour component. However, viewed in the context of established tumours, the
interactions between stromal components appear to be multifactorial given the level of one component e.g.
vasculature, does not correlate tightly with another, such as the macrophage.
Keywords: Cancer, Transcriptomics, Coexpression, Disease networks, Clustering, Modules, Gene signatures, Stroma
Background
In recent years the field of cancer research has seen an
increasing number of large gene expression studies of
primary human tumours. Analysis of these datasets has
tended to focus on the identification of markers able to
divide disease samples into prognostically relevant classi-
fications [1-5]. In the seminal paper by Alizadeh et al.
[6] they were able to subdivide lymphomas on the basis
of their gene expression profiles and thereby associate
specific genes with the tumour’s clinical characteristics.
Subsequently, numerous studies have attempted to classify
other tumour types based on their gene expression
profiles and others to stratify patients into the most
appropriate treatment group. The latter whilst not yet
driving therapeutic options, clearly has potential implica-
tions for individualised patient therapy [4,7]. These studies
have generally focused on the identification of groups of
differentially expressed genes that can be used to divide
tumours into subgroups using statistical approaches.
Such predictive gene signatures are frequently composed
of genes with no obvious shared biological function.
Indeed, there may be a number of signatures derived for
essentially the same purpose that share few if any genes in
common [8].
An alternative approach is to generate signatures that
reflect a specific biological process or outcome [9-11] or
sets of coexpressed genes based upon correlation matrices
[12-14]. One issue complicating analysis of any cancer
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gene expression data is the heterogeneity of samples. The
tumour cells themselves differ not only in the nature of
the mutation(s) that have driven them, but also the geno-
type of the patient and the treatment that they have
received. A significant proportion of a tumour mass is
comprised of stromal cells [15]; these non-transformed
cells forming the microenvironment in which tumour cell
growth is contained and supported. Indeed, the tumour
stroma is increasingly seen as an alternative target for
therapeutics with potential treatments targeting angiogen-
esis [16,17], the extracellular matrix [18] or immune cells
[16,19].
One approach to analysis of the cancer versus the
stromal components in a tumour is to employ laser cap-
ture microdissection e.g. [20]. Here we present an in
silico approach to dissecting the expression profiles
of individual cell types in the tumour stroma, as well as
the cancer cell component. We have developed a com-
putational framework and associated tool that now
supports visualization and clustering of very large correl-
ation networks derived from microarray expression data
[21,22]. The approach takes advantage of the heterogen-
eity of tumour samples. The underlying premise of this
approach is that the expression of genes specifically as-
sociated with a given cell type or pathway will increase
or decrease with the relative abundance or activity of
those cells/pathways within a given sample, either
because of genuine biological variation or random sam-
pling of different regions of the tumours (Figure 1). The
relative significance of correlation increases with the size
of the dataset, as the probability of coexpression occur-
ring by chance decreases. Modelling these associations
as a graph brings together groups of functionally associ-
ated genes which share similar expression profiles such
that they form cliques of high connectivity in a graph.
We have recently confirmed this hypothesis through the
meta-analysis of large collections of expression data de-
rived from many different populations of mouse cells
[23,24], pig tissues [25] and clinically derived samples
[26]. Here we demonstrate using individual cancer
datasets that global expression patterns can be divided
into biologically meaningful clusters defining tumour
cell and stromal elements, and also that many of these
gene signatures are conserved across multiple unrelated
human cancer datasets.
Results and discussion
Network topology
Following download of all cancer data it was subjected
to rigorous QC as poor quality data can have a signifi-
cant and detrimental effect on correlation network top-
ology. Only data that passed QC was used to construct
the large networks described here. Network topology
was visibly complex (Figure 2) and unsupervised cluster
Figure 1 Rationale behind the study. The relative number of a specific cell type or activity of certain pathways will vary across a
collection of individual tumours. For example, the macrophage content (Φ) will differ in every tumour and so therefore will the mRNA level of
macrophage specific genes (in blue). Similarly in every tumour at the point it is sampled the number of cells in mitosis (the mitotic index) will
differ and this will be reflected in different levels of expression of cell cycle genes (in red). As a result the expression level of genes specifically
expressed by those cells or associated specifically with the pathways will vary accordingly. By calculating the correlation coefficient between
every gene on the array and every other gene on the array it is possible to calculate a correlation matrix that includes all these correlation
coefficients. Graphs are then used to visualise relationships above a given correlation threshold and clustering used identifying groups of
co-expressed genes.
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analysis using the Markov clustering (MCL) algorithm
[27] defined cliques of highly connected nodes in all
graphs. Each clique (cluster) represented transcripts
whose expression patterns were highly correlated across
the dataset. These were surrounded and linked by
sparser network structures. GO and pathway enrichment
analysis was able to demonstrate functional enrichment
in many of the clusters, but was generally poor in identi-
fying clusters associated with the specific cell types from
which some of these signatures were clearly derived. We
therefore supplemented this analysis by comparison with
gene sets (clusters) derived from datasets of isolated tis-
sues and purified cell populations [28,29] and mining of
the literature. All graphs described in this work are avail-
able from the website www.OncoGraph.org which sup-
ports the direct visualization of graphs in BioLayout
Express3D using Java web start technology.
Technical replicates and functionally related genes are
closely associated in the graph network
Data derived from different probesets designed to the
same gene, genes in the same loci and functionally re-
lated genes were frequently found to be connected
within the graphs. For example in the testicular dataset
the six probesets designed to haemoglobin alpha (HBA1)
and three designed to haemoglobin beta (HBB) clustered
together reflecting the known co-regulation of these loci
(Figure 3a). Likewise the multiple probesets for the
growth hormone genes, GH1 and GH2, were closely as-
sociated within the testicular network graph alongside
the chorionic somatomammotropin hormones (CSH1,
CSH2, CSHL1) which are all sited at the same loci on
chromosome 17 (Figure 3b). Furthermore, two clusters
of Hox genes were found to be co-expressed in certain
testicular cancers (Figure 3c). Finally, markers of mono-
cyte/macrophage populations CD14, CSF1R and CD163
were all expressed at highly variable levels across indi-
vidual tumours but exhibited very similar profiles across
the dataset. Indeed, these markers were always closely
associated within all graphs and were usually all present
in a single MCL cluster. Furthermore, these clusters
were also enriched with many other genes also known to
be expressed in macrophages (for example gene list of a
macrophage cluster derived from DLBCL, see Additional
file 1). In a cluster such as this in which many of the
genes can be associated with a given cell type, the cluster
provides a unique insight into the functional profile of
the cell within the tumour. Although many of the genes
in such clusters are not recognised markers of these cells
and are therefore only characterised as such by the
principle of ‘guilt by association’, they may be of signifi-
cant interest in terms of defining the functional activity
of cells or as potential targets for manipulating cell
function.
Figure 2 Network graphs derived from six cancer datasets; a) breast carcinoma, b) colorectal carcinoma, c) DLBCL, d) glioma,
e) ovarian carcinoma and f) testicular germ cell tumours. Each dataset studied had its own idiosyncrasies owing to the tumour-specific biology
each represents and the high degree of inherent variation in gene expression data derived from cancer samples. In order to visualise and analyse
a large proportion of the expressed genes in these samples we aimed to construct graphs of data derived from individual cancer types based on
just under half the transcripts represented on the chip (18,000-23,000 probesets). For these reasons relatively low correlation thresholds were used
for graph construction i.e. between r = 0.65-0.75. The resultant graphs of individual cancer datasets are highly structured and composed of a large
number of nodes and edges (18,934 - 23,015 nodes, connected by between 268,471 - 954,082 edges, see Table 1 for details).
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Individual tumour datasets form unique network
structures related to the specific mix of cell populations
In previous studies of mouse primary cells and tissues
[21,23,24] we were able to identify clusters associated
with specific cell populations and others that reflected
particular cell functions. This was possible because cells
vary in their relative activity of different aspects of cell
biology e.g. growth and proliferation, metabolism, pro-
tein synthesis and secretion, endocytosis, motility etc.
Similarly, in this analysis many clusters showed clear
functional enrichment of genes encoding proteins asso-
ciated with a cell-specific pathway or cellular process
(Figure 4). Some clusters were common to all datasets
and some, such as neuronal signatures in the glioma
dataset or tissue signatures in teratomas, were specific to
individual tumours. Across all tumour types there were
closely related clusters of genes associated with cell cycle
progression, similar to cell cycle signatures observed
previously in other datasets [30,31]. The profile of these
genes reflected the known relative proliferative rate of
the tumour with, for example, expression at a higher
level in aggressive types of ovarian tumours compared to
those of a low malignant potential. A prominent cluster
found in all graphs was formed of genes associated with
the extracellular matrix (ECM); an expression signature
also evident in mouse data and analysed with respect to
human connective tissue-related diseases [32]. Expres-
sion of genes in this cluster was higher in tumours
characterised by a fibrotic stroma, for example
expression of these genes being elevated in primary me-
diastinal lymphoma (PMBL) as compared to other
subtypes of DLBCL. Other small clusters contained
known functional markers of endothelial cells (PECAM1,
EMCN, ESAM, VWF), smooth muscle cells (CNN1,
MYH11, TPM2) and adipocytes (AQP7, CD36, FABP4,
LPL). However, the predominant stromal expression
signatures are clearly associated with specific cells or ac-
tivities of the immune system. Clusters enriched for
markers of the monocyte/macrophage (CD14, CD163,
CSF1R), T cell (CD2, CD3, CD7, GZMA), and interferon
response (IFI1-3, MX1/2, OAS1-3) were present in all
tumour types studied here, and their composition was
essentially tumour-type independent. There was no evi-
dence of skewing of the macrophage profile towards any
particular phenotype. B cell-specific markers and related
genes were present in the immune-related networks of
some cancers but not others. In all tumours there was a
prominent signature representing a post-germinal centre
B cell/plasma cell which was rich in immunoglobulin
genes as well as markers of post-germinal centre B cells
such as IRF4. A neutrophil signature was identified only
in the colorectal cancer dataset, reflecting the presence
histologically of neutrophils in this tumour type.
In all of the graphs there were also many clusters of
genes showing relatively uniform expression across sam-
ples. Many of the genes that formed these clusters were
poorly annotated limiting the possibility of assigning any
functional linkage between them but are likely to play a
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Figure 3 Clusters of transcripts (left) derived from the testicular cancer dataset and (right) associated expression profiles (average
signal per gene or cluster). The individual tumours (represented along the y-axis) were grouped by mixed (green in upper bar) or pure
histological subtype (red in upper bar) and then by components present (coloured blocks in lower bar) a) Haemoglobin cluster containing data
derived from 5 probesets designed to HBA1 and 3 designed to HBB. The haemoglobin locus cluster is found to be present in many human
expression datasets and is often unconnected to any other genes. b) Cluster of somatotrophin genes whose expression is normally tissue specific
and limited to pituitary and placenta, shown here to be expressed predominately in tumours containing elements of choriocarcinoma, a tumour
formed of malignant trophoblast cells, the normal equivalent of which are involved in placenta formation. c) HOX genes found to be expressed
only in two teratomas with secondary carcinomatous transformation. Interestingly one of these tumours shows a high degree of up regulation of
one group of primarily HOXB genes and the other a mix of HOXA/C/D genes.
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role in uncharacterised cellular housekeeping functions.
In mouse data also, cell lineage-specific or inducible ex-
pression of genes are associated with more informative
annotation, reflecting the priorities of studies on gene
function [23].
Disease networks
Recognised markers associated with specific cancer sub-
types often did not fall within large clusters, presumably
because they are not highly correlated with global bio-
logical features of cancer cells or the associated stroma.
For example in the breast cancer dataset, there was a
small component of the graph representing genes whose
expression is lower in basal-like and ERBB2-positive tu-
mours (Additional file 2). This component included
ESR1 (oestrogen receptor alpha), GATA3, FOXA1 and
XBP1, and therefore appears to capture a significant pro-
portion of the oestrogen signalling transcriptional net-
work, including modulators and downstream targets.
GATA3 is involved in luminal differentiation in normal
breast tissue [33] and ESR1 and GATA3 have been
demonstrated to reciprocally regulate each other [34].
GATA3 is an inducer of FOXA1, which in turn can in-
duce XBP1, while ESR1 acts both upstream and along-
side FOXA1 (reviewed in [35]). Similarly, in the DLBCL
dataset, IRF4, one of the markers of the ABC-subtype
[6] lies in a sparse network on the edge of the graph,
whose nearest neighbours include FOXP1, PIM2 and
CARD11, all described to be up-regulated in ABC-
subtype of DLBCL, with amplifications or mutation
affecting FOXP1 [36] and CARD11 [36] identified
in 38% and 10% respectively of tumours studied
(Additional file 3). In both cases it would appear that the
graphs have accurately identified key disease modules as-
sociated with ESR1 or IRF4 and other genes lying in the
immediate neighbourhood merit further investigation.
An additional disease module [37], was associated with
SILV in the skin cancer data [38]. The immediate neigh-
bours of SILV, a gene whose product pMel17 is used
clinically in the diagnosis of melanoma [39], includes
TYR (tyrosinase) the key enzyme in melanin biosyn-
thesis, MLPH (melanophilin), which plays a role in
melanosome transport, GPR143 expressed on the mela-
nosome membrane and MLANA (melan-a). Also present
was MITF, a melanocytic transcription factor and tran-
scriptional regulator of many of these genes (reviewed in
[40]) and SNCA (alpha-synuclein).
Networks constructed based on the mean Pearson
correlation values across multiple datasets identify
conserved transcriptional signatures
Having examined gene expression signatures within
individual datasets, we questioned whether these signa-
tures were preserved across different tumour types.
Using six datasets (breast, colonic, DLBCL, glioma, ovar-
ian, testicular) a full correlation matrix was calculated
Figure 4 Network derived from testicular cancer dataset (Pearson correlation threshold r = 0.75). a) Network with only edges showing
allowing visualization of the inherent complex topology of the graph and b) with nodes shown where nodes are coloured according to cluster
membership. c) Graph with selected clusters shown and d) the average expression profile of genes within those clusters. (Cluster colour code is
maintained across graphs in this figure). Cluster 68 is highly enriched with endothelial marker genes and cluster 23 contains many transcripts
known to be associated with extracellular matrix. The last three selected clusters can be associated with different aspects of the immune infiltrate
in these tumours. Cluster 2 contains many know markers of T-cell and B-cells, cluster 4 (also shown in Figure 2) is enriched with many known
macrophage expressed genes and cluster 10 is highly enriched with many interferon response genes.
Doig et al. BMC Genomics 2013, 14:469 Page 5 of 16
http://www.biomedcentral.com/1471-2164/14/469
for each and the mean Pearson correlation coefficient
across the datasets calculated between all combinations
of probes. Layout of a graph derived from the mean
Pearson values (r = ≥0.6) across the six different tumour
types resulted in a smaller graph than those derived
from individual tumours at this threshold (Figure 5).
The topology of this graph broke down into three
main components which draw together clusters enriched
in genes associated with broad functional groupings.
The dominant topological feature contained four of the
five largest gene clusters. Many of the genes in these
clusters are poorly characterised but relatively uniformly
expressed across all samples in all datasets and were
therefore designated the ‘house-keeping’ (HK) clusters.
In general these clusters were poorly conserved in indi-
vidual datasets although areas of the graphs enriched in
housekeeping clusters were clearly identifiable.
A second portion of the graph was highly enriched
with genes encoding cell-cycle or cell-cycle related
proteins. Cluster 6 contains multiple cyclins, kinesins,
a
b
Cluster 3
House Keeping
(clusters 1,2,4,5)
ECM
(Cluster 9)
Plasma Cell
(cluster 14)
Cell Cycle
(cluster 6)
Immune
(clusters 7,8,12,13,19)
Cell Cycle Related
(cluster 10, 16, 26)
Figure 5 Network graph of conserved transcription signatures in cancer. a) 3D graph layout with labelling of main features in the network’s
topology. A graph of 9,882 nodes and 184,563 edges was created at Pearson threshold r≥0.6. Clustering of the graph using the MCL algorithm
resulted in 639 clusters ranging in size from 1,008 nodes to 4 nodes. A number of large clusters were shown to be highly enriched in genes
associated with expression in individual cell types and/or associated with specific cellular functions. See Additional files 3 and 4 for details
b) Collapsed cluster diagram showing the conserved gene network as a simplified 2D-network where single nodes represent a gene cluster and
are sized according to the number of transcripts within the cluster, edges represent connections between members of each cluster. Nodes
representing the main clusters have been coloured according to functional groupings. Blue - clusters represent those associated with
housekeeping functions; green - clusters of genes which are directly involved in cell cycle progression or whose expression is in way some linked
to it; pink - genes associated with the immune component of the tumour and yellow - other stromal elements. Smaller clusters enriched with
genes of known function are also shown.
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members of the minichromosome-maintenance-complex,
E2F transcription factor family members, DNA polymer-
ases and topoisomerase. The Aurora kinases (AURKA,
AURKB), BUB1 and both checkpoint proteins (CHEK1
and 2) are also present along with many other genes
that have previously been associated with the cell cycle
(see Additional file 4 for the full list of genes/clusters
and Additional file 5 for an enrichment analysis of
these clusters). Associated with the cell cycle cluster
are further smaller clusters e.g. clusters 10, 16 and 26
enriched in mitochondrial, ribosomal and glycolysis-
related genes.
The third main area of the graph is clearly associated
with different elements of the tumour stroma with a
number of immune-related gene clusters in close prox-
imity to each other and those representing other stromal
components being somewhat more distant. The macro-
phage cluster (cluster 7) from the combined cancer
graph contains many genes considered to be specific to
the myeloid lineage including CD68, CD14 and CSF1R.
There is also enrichment for lysosomal genes, multiple
genes involved in chemotaxis, and multiple toll-like re-
ceptors as well as scavenger receptors CD163, MARCO,
MSR1 which have previously been described by many
groups as expressed in tumour-associated macrophages
(see [41] for a review). Also, within the macrophage
cluster are multiple components of the MHC class II
antigen processing machinery. Interestingly, among the
genes also expressed is CD86, the co-stimulatory mol-
ecule, suggesting that these cells may be able to effi-
ciently present antigen to T cells. The T cell cluster
(cluster 8) contains pan-T cell markers (CD2, CD3, CD7)
and elements of the T cell receptor signalling cascade
(ZAP70, LCK, VAV, ITK). There are many chemokines,
cytokines and their receptors in the cluster (CXCL9,
CCL19, CCL5, LTB, CXCR3, CXCR6, CCR7, CCR2,
CCR5, IL2RB, IL2RG, IL17R, IL10RA) including also
interferon gamma (IFNG), the prototypical ‘classical’
macrophage activator. The T cell signature is suggestive
of an active state with expression of cytotoxic molecules
granzymes and perforin as well as markers of activation
(CD69). Lying adjacent to the T cell and macrophage
clusters is a cluster of genes many of which have been
associated with an interferon response containing ele-
ments of the proteasome and multiple interferon regula-
tory factors and interferon inducible proteins.
The largest non-immune-related element of the stro-
mal signature is a cluster of genes associated with extra-
cellular matrix which are almost certainly expressed
specifically in fibroblasts/myofibroblasts. It contains
structural proteins including many collagens as well as
cadherins, laminins, fibrillin and integrins. The signature
also contains modifiers of the extracellular matrix
such as MMP2, LOXL1, ADAMTS12, ADAMTS2 and
receptors for growth factors (PDGFRB) and shares a
high degree of overlap with the ECM signature derived
from mouse [23,32]. The vascular signature fragments
into four small but closely aligned clusters, three of
which appear to represent endothelium and the fourth
associated with the basement membrane/extracellular
matrix component. These clusters contain classical and
well characterised markers of vascular differentiation
such as PECAM1 (CD31), CD34, VWF, KDR and CDH5.
In addition, they contain many genes that have been
identified as endothelial specific genes by alternative bio-
informatic analysis approaches (ECSCR, EMCN, ROBO4,
TEK, EPAS1, GPR116) [42-45], components of the
Notch signalling pathway and other endothelial genes
which have been demonstrated in normal and tumour
associated endothelium such as PLVAP [46]. Finally
there is a small cluster that contains many adipocyte
specific genes including ADH1B, ADIPOQ, FABP4 and
LPL. Other small clusters or groupings of small clusters
of note contain the Affymetrix control probes, histone
complexes, AP1 transcription factors/early response
genes (JUN, JUNB, FOS, EGR1, EGR3, IER2, NR4A1,
NR4A2, ATF3, CTGF and DUSP1) and as mentioned
previously somatotrophins (GH1, CSH1, CSH2, CSHL2).
Core signatures are conserved in an unrelated dataset
In order to confirm that the ‘core’ transcriptional signa-
tures generated from the meta-analysis of six datasets
are conserved in other cancer datasets, we mapped the
signatures onto a number of completely independent
tumour datasets derived from skin/melanoma [38], gas-
tric cancer [47] and Hodgkin lymphoma [48]. In each
case clusters derived from the meta-analysis of the six
tumours identified corresponding clusters in these inde-
pendent datasets. Shown here are the results of their
comparison to a dataset consisting of primary skin can-
cers including basal cell carcinomas (BCC), squamous
carcinomas (SCC) and melanomas, plus a number of
metastatic melanomas [38]. Like the other independent
datasets, this contained unique transcriptional signatures
corresponding to the different tumour types represented
in this dataset (Figure 6). However the core signatures
were clearly also present. For example, cluster 16 (desig-
nated ‘macrophage’) in the skin cancer dataset was
highly significantly enriched for genes found in the
macrophage cluster in the ‘merged’ dataset (cluster 7 in
Figure 5) (adjusted p-value = 1.3E-120) implying that these
genes represent a true ‘functional unit’, in this case a cell
signature. Similarly cell cycle, stromal and house-
keeping clusters were also conserved in the skin cancer
data (Table 1) and all other cancer datasets so far exam-
ined have all generated networks where the conserved
signatures identified here have been found to be present.
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This study demonstrates the feasibility of an in silico
alternative to laser capture microscopy to identify the
gene expression profiles of the cells that make up a
tumour. Understanding the microenvironment of the
tumour allows exploration of potential new targets for
therapy, directed not at the malignant cells, but at the
environment in which they exist. Study of these cells is
complicated by the heterogeneous background in which
they exist and isolation of the cells from their back-
ground, unless by approaches such as microdissection,
will inevitably change them. Any clinically relevant
approach to the microenvironment must of necessity,
address the microenvironment of the established
tumour, rather than the factors that contribute to
tumour development. We have used BioLayout
Express3D a visualization tool that allows exploration of
complex networks of a size not previously possible [21].
Furthermore, we have used the MCL algorithm [27] to
group nodes (genes) into clusters in a completely un-
supervised manner. In this respect MCL has been shown
to perform as well or better than other network cluster-
ing algorithms [49]. Previous efforts to identify gene
signatures/modules in cancer data have used different
analytical approaches, less data, grouped far fewer genes
and often failed to explain the biological significance of
their findings [9-11,50,51]. Where correlation networks
have been used previously to analyse modularity in gene
expression data [13,52], available computing frameworks
have not permitted the visualization or exploration of
the resultant graphs as effectively in the current study.
The robustness across different datasets, and the obvious
association of genes of known function or cell lineage-
restriction, provides a strong internal validation for our
approach.
The preservation of specific clusters associated with
stromal cells across such a large number of genetically
diverse individuals and multiple tumour types argues
there is a common tumour microenvironment that con-
trols, and is controlled by, interactions amongst ele-
ments of the stroma. There is already a wealth of data
on the role of the tumour associated macrophage
(TAM), with the majority of studies suggesting that large
numbers of TAMs are associated with poor prognosis
(reviewed in [53,54]). Macrophages have been attributed
functions in assisting invasion, promoting angiogenesis
and subverting an immune response to the advantage of
the tumour. To date there are only global gene expres-
sion profiles from TAMs derived from inbred mouse
tumour models in which the cells have been separated
from their microenvironment and therefore potentially
had their gene expression altered by the process of
isolation. Our core macrophage signature contains genes
involved in phagocytosis, MHC class II antigen presenta-
tion and T cell co-stimulation and is therefore suggestive
of a macrophage acting as an antigen-presenting cell.
The TAM profile also contains scavenger receptors and
genes involved in lipid metabolism suggesting a role in
apoptotic cell clearance by TAMs. Analysis of the T cell
profile demonstrates the presence of an almost com-
pletely intact antigen recognition and signalling pathway
a b
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Figure 6 Conservation of transcriptional signatures in graph derived from skin cancer dataset (Pearson correlation threshold r = 0.80).
In order to provide a clear view of transcripts/clusters within skin cancer graph it has been simplified. The network shown here has been
constructed with a central framework of edges derived from the relationships between clusters and nodes representing the transcripts in each
cluster joined to a central node representing the cluster with the graph laid out in 2D. Only clusters comprising more than 8 probesets were
included. a) Colours represent different clusters in the skin cancer data, and b) overlay of clusters from the merged cancer (r = 0.6) graph
displayed using larger nodes. Many of the housekeeping clusters (1–5, 11) can be seen to be conserved, as is a proportion of the cell cycle (6),
macrophage (7), T-cell (8), ECM (9), interferon response (12), plasma cell (14), MHC class 1 (19), histones (20) and Affymetrix control (23) clusters.
However it can also be seen that many of the skin cancer clusters are not represented in the merged cancer profile set, these transcriptional
signatures being unique to skin cancers.
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Table 1 Summary of the gene coexpression clusters conserved across all datasets studied here
Descriptive
class
Cluster
description
Cluster ID
number
No. of
probesets
in cluster
No. of genes
in cluster
Known markers
present in cluster
Gene ontology
annotation
Other annotation Conservation of
signature in skin
dataset: Cluster
number
Conservation of
signature in skin
dataset: significance
of enrichment
* KEGG pathway, **
Curated gene set, ***
Swiss-Prot
(p-value for
EASE score)
Keywords (p-value) (Adjusted
Fisher’s test)
Immune Macrophage 7 220 163 CD68, CD14, CD163, CSF1R, Fc
Receptors (CD16, CD32, CD64),
MHC II molecules
Immune system process
(3.96e-32)
16 1.3E-120
Defence response
(8.79e-22)
T cell 8 181 145 CD2, CD3, CD6, CD7, CD52,
TCR
Immune system process
(4.99e-35)
TCR signalling pathway
(6.1e-25) *
6 3.29E-93
Signal transduction
(7.32e-18)
T cell activation (2.58e-
19)
Macrophage/T
cell interface
13 87 58 Immune response
(7.20e-06)
34 2.6E-13
IFN response 12 115 73 GBP1. IFI27, IFR1, IRF2, OAS1,
SP100, STAT1,
Immune response
(4.32e-26)
Genes upregulated by IFNB
in HT1080 (1.48e-47)**
51 4.06E-56
Response to virus
(1.15e-21)
Genes upregulated by IFNA
in HT1080 (1.05e-43)**
MHC class I 19 35 16 HLA-A, HLA-B, HLA-C, HLA-E,
B2M
Antigen processing and
presentation (5.51e-17)
MHC 1 (9.29e-15)*** 82 1.2E-58
Ig/ plasma cell 14 85 36 Ig light and heavy chains, Immune response
(7.49e-10)
Ig C region (1.12e-10) 21 2.48E-129
B-cell 79, 142 10, 7 6, 6 CD19, CD20, CD79 B-cell receptor complex
(2.31e-06)
BCR signalling (1.28e-09)* 6 6.52E-17
Immune response
(1.84e-08)
Mast cell 93 9 4 Tryptase, Fc receptor for IgE Proteolysis (0.008) Zymogen (4.77e-04)*** 167 2.72E-27
AP1 response 48, 89 13, 9 11, 6 FOS, JUNB, Sequence specific DNA
binding (2.19e-06)
DNA binding (2.75e-09)*** - -
Regulation of cellular
process (1.2e-04)
Stroma Extracellular matrix 9 163 100 BGN, CALD1, FN1, collagens Extracellular matrix
(1.93e-40)
88 5.5E-34
Cell adhesion (1.16e-17)
Adipocyte 27 22 15 ADIPOQ, LPL Response to wounding
(0.004)
PPAR signalling (1.46e-07)* - -
Adipocyte vs Fibroblast
upregulated (1.49e-15)**
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Table 1 Summary of the gene coexpression clusters conserved across all datasets studied here (Continued)
Endothelium 29,38,49 20, 17, 13 17, 13, 11 CD31, CD34, Endomucin,
Endoglin, vWF
Cell adhesion (1.3e-08) Upregulated in glomerul in
DM vs normal (8.33e-14)**
58 6.75E-16
Blood vessel
development (1.28e-10) Brentani_Angiogenesis
(6.87e-08)**
Endothelium/ECM 59 11 6 COL4A1, COL4A2 Cell adhesion (4.13e-05) 215 1.22E-12
Smooth muscle 88, 249 9,6 5, 4 Alpha SMA, calponin Smooth muscle
contraction (4.75e-05)
Muscle protein (3.95e-08)*** 907 1.27E-11
Skeletal muscle 46 15 15 Myoglobin, CKm, Myosin Contractile fibre part
(1.53e-17)
23 2.55E-31
Muscle development
(2.09e-05)
Cell cycle Cell cycle 6 239 182 AURKA, BUB1, CHEK2, CDC2,
MCM2
Cell cycle (3.06e-59) Serum fibroblast cell cycle
(1.17e-117)**
101 1.31E-26
DNA replication
(1.48e-39)
Cell cycle related 10, 16, 26 147, 52,
23
125, 44, 19 RNA binding (2.29e-11) RNA binding (2.29e-14)*** - -
Ribosomal Ribosomal 54, 60, 64,
97
12, 11, 11,
8
12, 8, 6, 5 RPL38, RPS10, RPS19 Cytosolic ribosome
(7.91e-13)
Ribosomal protein
(8.44e-11)***
54 4.25E-36
Protein biosynthesis
(1.62e-06)***
Other
functional
classes
Histones 20 30 26 HIST1H1C, HIST1H2AB,
HIST1H3H
Nucleosome (9.75e-23) Nucleosome core
(2.61e-21)***
160 9.15E-35
Chromatin assembly
(9.24e-21)
Glycolysis 47 13 5 GAPDH, GPI Glycolysis (1.46e-05) Gluconeogenesis
(9.37e-07)***
151 6E-30
Haemoglobins 91 9 2 HBA1, HBB 144 6E-31
Affymetrix
controls
Affymetrix
controls
23, 28 26, 22 26, 22 99 4.57E-59
Each cluster or group of related clusters has been placed into a functional grouping based on the biology from which it is derived. Details of the cluster(s) are provided together with selected pathway/Gene ontology
enrichment scores for the genes that make up the clusters. (For a complete list see Additional file 4).
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containing elements of the TCR, co-receptors and down-
stream signalling molecules. Also in the signature are
cytotoxic molecules and markers of activation suggesting
these are, at least in part, activated cytotoxic T cells. The
preservation across all tumour types of a cluster of genes
associated with an interferon response and the presence
of IFNG in the T cell signature argues that activation of
this pathway forms a consistent part of the response to a
tumour. This is also in keeping with data derived from
murine models in which it was shown that TAMs
express many interferon inducible genes [55]. Taken
together, these data do not support the view that TAMs
have a so-called M2 (or alternative activation) [19]
phenotype characterised by dominant actions of
interleukin 4. Nor does the analysis support the view
that recognition of tumour-associated antigens is
compromised by a lack of antigen-presenting cells.
One of the larger signatures observed is associated
with the extracellular matrix. This was enriched in struc-
tural proteins, proteoglycans, modifiers of the extracellu-
lar matrix and signalling molecules. Histologically, the
presence of a desmoplastic tumour stroma is a well
recognised phenomenon occurring in many tumour
types. However, like many other elements of the micro-
environment the precise role played by this reactive
stroma has been difficult to assess: is the role of the
stroma to contain the tumour or is it yet another factor
recruited to promote the survival of the malignant cells?
Recent data from studies of DLBCL suggest that in this
tumour at least the answer may be that different ele-
ments of the stroma contribute to both a good and a
poor prognosis [56], whereas work in small cell carcin-
oma has established the role of interactions between the
ECM and tumour cells in resisting chemotherapy-induced
death [57]. More recently work in a lung carcinoma model
[58] highlighted the role that ECM components, in this
case versican, can play in activating other elements of the
microenvironment suggesting that as for other elements
of the tumour microenvironment, cross-talk between ele-
ments is likely to be of great importance.
The vasculature signature observed here contains
many well characterised markers of endothelial cells as
well as less well characterised endothelial genes. It con-
tains receptors and co-receptors (KDR, NRP2) for VEGF,
the major angiogenic factor but also contains elements
associated with Notch signalling, another important sys-
tem in angiogenesis (for a review see [59]). NOTCH3,
usually expressed in vascular smooth muscle, lies in the
endothelial-related cluster enriched in ECM and base-
ment membrane proteins. A recent study investigated
the crosstalk between endothelial and mural cells via
NOTCH3 signalling and showed a reduction in angio-
genesis in an in vitro co-culture system when NOTCH3
is knocked out in mural cells [60].
The fact that macrophage, T cell, ECM and
endothelial-specific genes form independent clusters, in-
dicates that there is not a tight causal relationship be-
tween them. The T cell signature and macrophage
signatures are to some extent correlated in all of the net-
works, but this does not necessarily imply an interaction
beyond the fact that the most fibrotic regions of a
tumour tend to exclude leukocytes so the two cell types
could be co-enriched by chance. Despite the reported as-
sociation of macrophage number with microvessel dens-
ity in some solid tumours [61-64], the signatures of
macrophages and endothelial cells are clearly separate,
so there is not likely to a strict macrophage requirement
for angiogenesis, and in fact the drive to angiogenesis is
likely to be multifactorial. This viewpoint is supported
by the fact that the macrophage cluster does not contain
any of the known regulators of endothelial proliferation,
such as the vascular endothelial growth factors (VEGFs).
Neither macrophage nor endothelial cluster contains
TIE2, which has been implicated, based largely upon
in vitro studies, in tumour-associated angiogenesis and
regulatory T cell production [65,66]. Indeed, the T cell
cluster does not contain FOXP3 or CD25, indicating that
regulatory T cell activation is not a ubiquitous feature of
the immune environment of tumours.
Conclusion
In summary, we have demonstrated a unique approach
to phenotyping cell types and identifying pathways
within cancer without the need for technologies such as
microdissection. The approach is related to the views of
pathways, interaction and functional relationship that
can be derived from analysis of introduced genetic vari-
ation in yeast [67]. The core signatures we report pro-
vide a tool to aid the analysis of further datasets, and
using the tool BioLayout Express3D they can readily be
overlaid on to other data as an aid to the interpretation
of other large-scale expression data. In considering
therapeutic approaches to cancer, our approach identi-
fies sets of genes that are common to a range of tumour
types, and to the stromal components, and which might
therefore be potential targets. It also identifies candidate
markers for assessing the mechanism and efficacy of
therapeutic intervention.
Methods
Selection and preprocessing of datasets
Datasets were selected on the following criteria; analysis
of primary human tumour samples, large study size,
availability of raw data with provision of clinical annota-
tion and genome-wide analysis using the Affymetrix
U133 platforms (either U133A + B or U133Plus2.0).
These datasets were identified from Gene Expression
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Omnibus (GEO) or caArray and CEL files downloaded.
See Table 2 for details.
The initial analysis used six individual datasets. The
breast cancer dataset [4] was stratified on the basis of
molecular tumour type (basal, HER2 positive, luminal A
or B, or normal-like), Ellis-Elston grade, and outcome.
The colorectal dataset [68] was divided into microsatel-
lite stable and unstable tumours. The lymphoma dataset
[69] was stratified into germinal centre B cell-like
(GCB), activated B cell-like (ABC), primary mediastinal
B cell (PMBL) and unclassified, based on gene expres-
sion and further organised on the basis of sex and
patient outcome. The glioma dataset, derived from
caArray, was stratified on the basis of histological type
(astrocytoma, oligodendroglioma, glioblastoma), WHO
grade and sex. The ovarian dataset [70] was stratified by
malignant or low malignant potential, histological type
(endometrioid or serous), grade, stage and primary site
(ovary, peritoneum or fallopian tube). The testicular
dataset [71] contained primary germ cell tumours and
was stratified by pure or mixed histological types and
then within each category on the constituent elements
using the WHO classification (seminoma, teratoma,
embyronal carcinoma, yolk sac tumour, choriocarcin-
oma). As such these data were selected to represent a
broad range of tumour biology. Other data derived from
various types of skin cancer including BCC, SCC, pri-
mary melanoma, and melanoma metastatic to subcuta-
neous tissue, lymph node, brain and adrenal gland [38],
gastric cancer [47] and Hodgkins lymphoma [48] were
used as test datasets to verify the conservation of gene
signatures in independent datasets.
A summary of the data analysis pipeline is shown in
Figure 7a. The quality of the raw data from each dataset
was reanalysed using the arrayQualityMetrics package
in Bioconductor (http://www.bioconductor.org/) and
scored on the basis of 5 metrics, namely maplot, spatial,
boxplot, heatmap and rle [72]. Any array failing on more
than one metric was removed (Table 2) and in cases
comprising A and B arrays, failure of one chip resulted
in removal of data for that patient from analysis. Where
the data was derived from A and B arrays, a single
merged file was created for each sample. Following QC,
each dataset was normalised independently using the ro-
bust multi-array average (RMA) expression measure
[73]. Probesets were annotated using Bioconductor (26
June 2009) and samples ordered according to clinical
grouping.
Network analysis
Each dataset was saved as an ‘.expression’ file containing
a unique identifier for each row of data (Gene symbol
concatenated to probeset ID), followed by columns of
gene annotations used as class-sets for the overlay and
analysis of information with respect to the graph, and
finally natural scale normalised data values for each sam-
ple (each column of data being derived from a different
sample). These files were then loaded into the network
analysis tool BioLayout Express3D [21]. Pairwise Pearson
correlations were calculated for each probeset on the
array(s) as a measure of similarity between the signal de-
rived from different probesets. All Pearson correlations
where r ≥ 0.6 were saved to a ‘.pearson’ file. Graph layout
was performed using a modified Fruchterman-Rheingold
algorithm [74] in 3-dimensional space in which
nodes representing genes/transcripts are connected by
weighted, undirected edges representing correlations
above the selected threshold. Depending on the size of
the dataset and the inherent variation of samples,
datasets produced graphs of varying sizes at a given cor-
relation threshold value (Figure 7b). Selected correlation
thresholds for individual datasets were designed to in-
clude approximately 40% of the available data (Table 2).
The resultant graphs were very large and highly
Table 2 List of the cancer datasets used for this study
Database reference Reference (PMID) Tumor type(s) Cases
analysed
Affymetrix U133
Platform(s)
Graph size
(nodes)
Graph size
(edges)
GSE11318 Lenz et al. (18765795) DLBCL 194 Plus 2.0 19,850 614,273
GSE1456 Pawitan et al. (16280042) Breast carcinoma 134 A & B 19,246 559,761
GSE9891 Tothill et al. (18698038) Ovarian (epithelial) carcinoma 265 Plus 2.0 19,415 268,471
GSE3218 Korkola et al. (16424014) Testicular germ cell tumours 86 A & B 18,934 954,082
GSE13294 Jorissen et al. (19088021) Colorectal carcinoma 150 Plus 2.0 22,687 725,467
caArray/rembr-00037 REMBRANT – Repository for
Molecular Brain Neoplasia Data
Primary CNS tumours 253 Plus 2.0 23,015 623,591
GSE7553 Riker et al. (18442402) Skin tumours 77 A & B 19,623 600,143
GSE17920 Steidl et al. (20220182) Hodgkin lymphoma 131 Plus 2.0 13,846 521,593
GSE15459 Ooi et al. (19798449) Gastric cancer 200 Plus 2.0 15,747 719,884
The datasets with a white background are the six used for the primary analysis and the remaining three (bold) the datasets used to confirm the robustness of the
core cancer expression signatures.
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structured (Figure 3). The topology of the graph
contained localised areas of high connectivity and high
correlation (representing clusters of genes with similar
profiles), were determined using the Markov Cluster
(MCL) algorithm which simulates multiple iterations of
random flow through the graph structure. An MCL in-
flation value of 2.2 was used as the basis of determining
the granularity of clustering, as it has been shown to be
optimal when working with highly structured expression
graphs [21]. Clusters were named according to their
relative size, the largest cluster being named cluster 1.
Graphs of each dataset were explored extensively in
order to understand the significance of the gene clusters
and their relevance to the pathology of the tumours.
Cluster annotation
Gene set enrichment analysis was performed on clusters
using DAVID [30,75] and GSEA MSigDB [31] web-
based analysis tools to determine the significance of co-
expressed genes. Clusters were annotated if hits of high
significance showed a common trend as to function.
These analyses were supplemented by comparison of the
clusters with tissue- and cell-specific clusters derived
from network-based analyses of a human tissue atlas
and an atlas of purified leukocyte populations [28,29]
and comprehensive reviews of the literature.
Comparison of expression patterns across Six cancers and
validation of signatures
To allow direct comparison of the datasets, probesets
that were not represented in all datasets i.e. were only
present on the U133Plus 2.0 array, were removed leaving
44,754 probesets common to all U133 platforms. The
Pearson correlation coefficient between data derived
from each probe-set in individual datasets was calculated
using BioLayout Express3D and all correlation values
written to file. A mean Pearson correlation was then cal-
culated for each transcript i.e. the average correlation
a
b c
Figure 7 Approach to data analysis. a) Flow diagram summarising the analysis pipeline used here. The size of graph generated from each
dataset at different Pearson correlation thresholds in terms of b) the number of nodes and c) number of edges.
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between probesets across the six datasets. Mean Pearson
correlations were filtered to remove any values below a
user defined threshold and network graphs constructed.
The work described here is based on the analysis of a
graph constructed using a mean Pearson threshold of
r ≥0.6 and clustered with an MCL inflation value of 2.2.
In order to analyse the conservation of the gene signa-
tures in an unrelated dataset, the clusters and associated
annotations derived from the merged r ≥0.6 graph were
mapped onto to datasets derived from various types of
skin cancer [38], gastric cancer [47] and Hodgkin’s
lymphoma [48]. Graphs were constructed from these
data and clustered, and these clusters were analysed for
enrichment of genes from the ‘core signatures’ using
Fisher’s test with an adjustment for multiple of testing.
Additional files
Additional file 1: Table of macrophage gene cluster derived from
DLBCL dataset when examined using a Pearson correlation cut off
of ≥0.65 and clustered using an MCL inflation value of 2.2.
Additional file 2: Coexpression clustering of genes associated with
ESR1 in breast cancer dataset. As expected the expression of ESR1
(below) shows a marked reduction in ER-negative tumours. Examination
of the neighbours of ESR1 in the correlation network pulls out many of
the known ESR1 targets including FOXA1, XBP1, ERBB4 and GATA3
together with some new and interesting candidate genes.
Additional file 3: Coexpression clustering of genes associated with
IRF4 in DLBCL dataset. IRF4, one of the markers of the ABC-subtype [6]
lies in a sparse network on the edge of the graph. Its nearest neighbours
include FOXP1, PIM2 and CARD11, all described to be up-regulated in
ABC-subtype of DLBCL, with amplifications or mutation affecting FOXP1
and CARD11 identified in 38% and 10% respectively of tumours studied.
Additional file 4: Cluster analysis of merged cancer (r = 0.6) graph.
This table lists the gene membership and annotation of each cluster
from the meta-analysis of gene expression data derived from multiple
tumour types.
Additional file 5: GO analysis of the main clusters of interest from
the combined cancer data analysis. All graphs and tables described in
this work are available from the website www.OncoGraph.org which
supports the direct visualization of graphs in BioLayout Express3D using
Java web start technology.
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